Helping Children Fight Liver Cancer with New Immunotherapy Treatment
NCT04134559 · RecruitingThis research study is looking at an immunotherapy drug called pembrolizumab, or KEYTRUDA, as a possible treatment for pediatric liver cancer. The goal is to see if this drug can help children with hepatocellular carcinoma or related liver tumors. It is a Phase II trial, which means the team is testing how well the drug works and how safe it is for young patients.
Locations and contact
This trial is running at 5 locations in the United States. All of them are currently recruiting.
United States5 locations · 5 recruiting
- Baylor College of MedicineHouston, TexasRecruiting
- Children's Hospital BostonBoston, MassachusettsRecruiting
- Cincinnati Children's Medical CenterCincinnati, OhioRecruiting
- Dana Farber Cancer InstituteBoston, MassachusettsRecruiting
- University of California San FranciscoSan Francisco, CaliforniaRecruiting
Who can join
This trial is open to children and young adults up to 30 years old. Participants must have a specific type of liver cancer that has not responded to other treatments. They also need to be well enough to tolerate the study drug and meet certain health requirements. The trial team will confirm if each person is eligible to join.
What happens during the trial
Everyone in the trial will receive pembrolizumab. This drug is given every three weeks at a dose based on the patient's weight. Each treatment cycle lasts for 21 days. The main goal is to see how the patients respond to the drug after about 63 days.
The trial team
The trial is led by Dr. Allison O'Neill at Dana-Farber Cancer Institute. Dr. O'Neill is the principal investigator responsible for the study.
Important dates
The trial started on November 1, 2020. It is currently enrolling new participants and is expected to finish by January 1, 2028.
Additional information
The trial is registered under NCT04134559. It is a Phase 2 trial, which means it is looking at how well the treatment works and how safe it is. This study involves 18 participants and is regulated by the FDA.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →